Recommended Topic Related To:

Nubain

"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...

Nubain




PATIENT INFORMATION

Patients should be advised of the following information:

- NUBAIN (nalbuphine hydrochloride) is associated with sedation and may impair mental and physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery.

- NUBAIN (nalbuphine hydrochloride) is to be used as prescribed by a physician. Dose or frequency should not be increased without first consulting with a physician since NUBAIN (nalbuphine hydrochloride) may cause psychological or physical dependence.

- The use of NUBAIN (nalbuphine hydrochloride) with other opioids can cause signs and symptoms of withdrawal.

- Abrupt discontinuation of NUBAIN (nalbuphine hydrochloride) after prolonged usage may cause signs and symptoms of withdrawal.

Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Chronic Pain/Back Pain

Find tips and advances in treatment.